Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Alnylam Pharma (0HD2) Financial Statements
0 Followers
Alnylam Pharma Financial Overview
| Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | - | ||||
| Total Revenue | $ 319.29M | $ 599.42M | $ 264.31M | $ 224.82M | $ 213.26M |
| Gross Profit | $ 264.42M | $ 548.16M | $ 223.19M | $ 184.01M | $ 177.63M |
| EBIT | $ -162.06M | $ 88.29M | $ -364.86M | $ -232.06M | $ -196.99M |
| EBITDA | $ -150.05M | $ 98.87M | $ -344.21M | $ -201.51M | $ -187.53M |
| Net Income Common Stockholders | $ -174.10M | $ 56.90M | $ -405.92M | $ -277.40M | $ -240.34M |
| Balance Sheet | - | ||||
| Cash, Cash Equivalents and Short-Term Investments | $ 2.07B | $ 2.19B | $ 2.27B | $ 2.11B | $ 2.24B |
| Total Assets | $ 3.39B | $ 3.55B | $ 3.54B | $ 3.33B | $ 3.43B |
| Total Debt | $ 1.32B | $ 1.32B | $ 1.32B | $ 990.98M | $ 995.39M |
| Net Debt | $ -750.33M | $ -872.16M | $ -941.45M | $ -1.12B | $ -1.24B |
| Total Liabilities | $ 3.65B | $ 3.55B | $ 3.60B | $ 3.15B | $ 3.03B |
| Stockholders Equity | $ -259.24M | $ -158.22M | $ -67.64M | $ 176.04M | $ 401.17M |
| Cash Flow | - | ||||
| Free Cash Flow | $ -180.37M | $ -153.61M | $ -131.79M | $ -138.87M | $ -189.05M |
| Operating Cash Flow | $ -166.47M | $ -131.98M | $ -115.28M | $ -122.82M | $ -171.19M |
| Investing Cash Flow | $ -76.22M | $ -139.91M | $ 313.89M | $ 142.79M | $ -147.42M |
| Financing Cash Flow | $ 46.37M | $ 63.44M | $ 297.02M | $ 30.34M | $ 34.96M |